FDA Approves Durvalumab Plus Chemo for Biliary Tract Cancer

The immune checkpoint inhibitor is already approved for use in lung cancer. Now it is also approved for use in combination with chemotherapy for locally advanced or metastatic biliary tract cancer.
FDA Approvals

source https://www.medscape.com/viewarticle/980227?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?